Anna Holovan

Dr. Anna Holovan


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017
Verified
Conference Paper
Open access
KNKrystyna Naumenko
Krystyna Naumenko
AHAnna Holovan
Anna Holovan
SZSvitlana D Zahorodnia
Svitlana D Zahorodnia
YSYuriy Shermolovich
Yuriy Shermolovich
On a global scale, Epstein-Barr virus (EBV) infects over 90% of the adult population and is responsible for ~1% of all human cancers. Fluorine is one of the most abundant elements on earth. However, it occurs extremely rarely in biological compounds. The introduction of the fluorine atom(s) into many biologically active molecules can bring about remarkable and profound changes in their properties. Development of potential drugs is closely related to in silico methods, which include PASS, QSAR, COMPARE-analysis and more. The aim of this work was to analyze the potential biological activity and the target of action of derivatives of bisphosphonic acids by using in silico methods and examined received results by in vitro study. For this purpose, PASS software, web-server PharmMapper, PCR, MTT assay, trypan blue and neutral red assay were used. According to PASS prediction two compounds (10s-20 and 10s-21) may possess antiviral activity, Pa/ Pi was 0,294/0,005 and 0,214/0,084, respectively. Also, all compounds may possess a cytochrome c as substrate. Several targets were identified by using molecular docking (PharmMapper). It was shown that a lot of possible targets are proteins, such as Gag-Pol protein (viral protein) and different kinds of protein kinases. A study in vitro shown anti-EBV activity for all compounds. On the other hand, derivatives of bisphosphonic acids had a high level of cytotoxicity on different lymphoblastoid cell lines. Therefore, the in silico screening presents a good approach for the development of new anti-EBV agents. Our results showed, that derivatives of bisphosphonic acids may possess apoptosis modulating properties for treatment of lymphoproliferative diseases.

31 October 2018
Verified
Conference Paper
Open access
KNKrystyna Naumenko
Krystyna Naumenko
AHAnna Holovan
Anna Holovan
GBGalyna Baranova
Galyna Baranova
SZSvitlana D Zahorodnia
Svitlana D Zahorodnia
AGAnna Gudz
Anna Gudz
YSYuriy Shermolovich
Yuriy Shermolovich
Epstein–Barr virus (EBV) causes lymphocyte-proliferative diseases, such as Burkitt’s lymphoma, Hodgkin’s lymphoma, other B and T cell lymphomas. Recently the connection between EBV and autoimmunity diseases has been demonstrated. In recent years, several studies have explored the concept that the compounds that have anti-herpetic activity might be able to influence the cell cycle of infected cells, by eliminating them from the body. However, cell cycle regulation during EBV-infection and the effect of anti-EBV drugs have received only limited attention. The aim of our work was to study derivatives of triazole (G14, G20, G22, and G24) as potential antiherpetic agent and their effect on the cell cycle of lymphoblastoid cell lines B95-8. According to PCR, anti-EBV activity was observed only for compounds G14 and G22, EC50 values were 27 and 100µg/ml. The В95-8 cells treated with all studied compounds were analyzed with the help of flow cytometry (cells were stained with propidium iodide). It was observed an induction of apoptosis in the presence of G22 at 700µg/ml; the proportion of apoptotic cells reached almost 40%. Other compounds G14 and G24 led to the switch of cells from the Sub G0 phase of the cell cycle to the G1 phase and subsequent activation of the S-phase. These compounds may play an important role as potential inducers of EBV lytic infection; with the addition of antiherpesvirus drugs, they could be therapeutically beneficial for EBV-associated tumors.

1 November 2016
Verified
Conference Paper
Open access
KNKrystyna Naumenko
Krystyna Naumenko
AHAnna Holovan
Anna Holovan
GBGalyna Baranova
Galyna Baranova
SZSvitlana D Zahorodnia
Svitlana D Zahorodnia
YSYuriy Shermolovich
Yuriy Shermolovich
In our laboratory, we focus on the design, synthesis, and evaluation of fluorinated compounds that could be used in the tretament of diseases caused by the Epstein-Barr virus (EBV) and virus vesicular stomatitis (VVS). EBV is a DNA-containing virus. It is characterized by an acute form of infection as well as a latent form, which may lead to cell transformation and to cancer (lymphoma, carcinoma). VVS is a RNA-containing virus. For this purpose, in a first step, we used the PASS software by which we could identify potential antiviral candidates among which a fluorinated derivative of uracil (G27), a trifluoromethyl-substituted derivative of a thiosugar (SBIO6), a bisphosphonic acid (10s19) and several derivatives of alanin and glucose (10s20 - 10s28). Our in vitro studies revealed an antiviral activity for a few compounds. Three compounds appeared to be effective against EBV: G27 (EC50 = 100 µg/ml), 10s20 (EC50 = µg/ml), and 10s25 (EC50 <62 µg/ml, replication of EBV was suppressed at 100 % at a concentration of 62 µg/ml). The ability to inhibit reproduction of VVS was showed for compound 10s19 (EC50 = 19 µg/ml) and for compound 10s24 (EC50 = 29 µg/ml). It was established that the index of selectivity for these compounds ranged from 10 to 100. As Epstein-Barr virus (EBV) is the cause of several lymphoproliferative diseases, we studied the potency of G27 and SBIO6 compounds to make an apoptosis induction. Apoptotic cells were detected using a flow cytometry. Addition of G27 led to the observation of two peaks in the histogram, what may indicate a break of the cell cycle by this compound. It was also established that by addition of SBIO6 the percentage of apoptotic cells was significantly increased when compared to the control and reached 70 - 90 percent.